BTIG analyst Ryan Zimmerman maintained a Hold rating on Zimmer Biomet Holdings (ZBH – Research Report) today. The company’s shares opened today at $127.61.
According to TipRanks, Zimmerman is a 5-star analyst with an average return of 9.7% and a 47.57% success rate. Zimmerman covers the Healthcare sector, focusing on stocks such as Intuitive Surgical, OrthoPediatrics, and Treace Medical Concepts.
Zimmer Biomet Holdings has an analyst consensus of Hold, with a price target consensus of $123.36, which is a -3.33% downside from current levels. In a report released today, Piper Sandler also maintained a Hold rating on the stock with a $135.00 price target.
See Insiders’ Hot Stocks on TipRanks >>
The company has a one-year high of $134.19 and a one-year low of $99.98. Currently, Zimmer Biomet Holdings has an average volume of 1.42M.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Zimmer Biomet Holdings, Inc. is a musculoskeletal healthcare company. The company engages in designing, manufacturing and marketing orthopedic reconstructive products; biologics, sports medicine, extremities and trauma products; spine, dental implants, bone healing, craniomaxillofacial and thoracic products; and related surgical products.
Read More on ZBH:
- Zimmer Biomet Announces Fourth Quarter and Full-Year 2022 Financial Results
- Increasing Medical Issues Bode Well for Zimmer Biomet Stock (NYSE:ZBH)
- Zimmer Biomet upgraded to Outperform from Sector Perform at RBC Capital
- Zimmer Biomet price target raised to $130 from $120 at Piper Sandler
- Zimmer Biomet to Acquire Embody, Inc.
